- Home
- PBYI vs CLLS Comparison
PBYI vs CLLS Comparison
Compare PBYI & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- CLLS
- Stock Information
- Founded
- PBYI 2010
- CLLS 1999
- Country
- PBYI United States
- CLLS France
- Employees
- PBYI N/A
- CLLS N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PBYI Health Care
- CLLS Health Care
- Exchange
- PBYI Nasdaq
- CLLS Nasdaq
- Market Cap
- PBYI 263.4M
- CLLS 299.0M
- IPO Year
- PBYI N/A
- CLLS 2007
- Fundamental
- Price
- PBYI $4.95
- CLLS $3.26
- Analyst Decision
- PBYI Strong Buy
- CLLS Buy
- Analyst Count
- PBYI 1
- CLLS 1
- Target Price
- PBYI $7.00
- CLLS $8.00
- AVG Volume (30 Days)
- PBYI 418.9K
- CLLS 144.9K
- Earning Date
- PBYI 11-06-2025
- CLLS 11-07-2025
- Dividend Yield
- PBYI N/A
- CLLS N/A
- EPS Growth
- PBYI 434.29
- CLLS N/A
- EPS
- PBYI 0.97
- CLLS N/A
- Revenue
- PBYI $238,062,000.00
- CLLS $63,438,000.00
- Revenue This Year
- PBYI N/A
- CLLS N/A
- Revenue Next Year
- PBYI N/A
- CLLS $66.76
- P/E Ratio
- PBYI $5.08
- CLLS N/A
- Revenue Growth
- PBYI 8.63
- CLLS 223.09
- 52 Week Low
- PBYI $2.32
- CLLS $1.10
- 52 Week High
- PBYI $6.07
- CLLS $5.48
- Technical
- Relative Strength Index (RSI)
- PBYI 45.94
- CLLS 42.10
- Support Level
- PBYI $5.14
- CLLS $3.17
- Resistance Level
- PBYI $5.52
- CLLS $3.79
- Average True Range (ATR)
- PBYI 0.25
- CLLS 0.22
- MACD
- PBYI -0.06
- CLLS -0.09
- Stochastic Oscillator
- PBYI 17.82
- CLLS 7.59
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.